Exploring the Therapeutic Potential of Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review
Hormone and Metabolic Research · 01.03.2026 · 58 (03) · 81-89
DOI: 10.1055/a-2787-1205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.03.2026. Verfasst von Sulthan Al Rashid und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology, Saveetha Institute of Medical and Technical Sciences (Deemed to be University), Chennai, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Transporter 2 Inhibitors, Fatty Liver. Die Arbeit nennt 39 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis are increasingly concerning health issues, especially in people with type 2 diabetes mellitus, where metabolic problems drive liver disease progression. While lifestyle changes remain essential, new drug strategies—particularly sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists—have gained growing interest for their potential to protect the liver. This review examines how sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists might help treat metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis, focusing on their mechanisms of action, study evidence, and results from meta-analyses. A thorough search of the literature found studies on how these drugs affect insulin sensitivity, liver fat, and inflammation. Preclinical models show that they can lower liver fat, reduce oxidative stress, and decrease fibrosis markers. Clinical trials and meta-analyses support their potential to improve liver enzyme levels, decrease liver fat, and slow fibrosis growth. Overall, sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists appear promising in the management of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis, especially in type 2 diabetes mellitus patients. Still, more long-term research studies are needed to confirm how well they work, how safe they are, and the best way to use them, either alone or in combination with other treatments. These drugs may represent important advances in the treatment of liver diseases linked to metabolic problems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacology, Saveetha Institute of Medical and Technical Sciences (Deemed to be University), Chennai, India.
- Medical Gastroenterology, Saveetha Institute of Medical and Technical Sciences (Deemed to be University), Chennai, India.
- Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, India.
- Clinical Pharmacology, Pharmacy practice, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.
- Pharmacology, College of Pharmacy King Khalid University, Abha 62223, Saudi Arabia.
- Pharmacy practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
ORCID-Profile: Rajkapoor Balasubramanian
Zitieren
APA
Al Rashid, S., Suriyan, A., Bilal Azam, M., Balasubramanian, R., Pakkir Maideen, N. M., Chidambaram, K., & Amirthalingam, P. (2026). Exploring the Therapeutic Potential of Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review. Hormone and Metabolic Research, 58(03), 81-89. https://doi.org/10.1055/a-2787-1205
Vancouver
Al Rashid S, Suriyan A, Bilal Azam M, Balasubramanian R, Pakkir Maideen NM, Chidambaram K, et al. Exploring the Therapeutic Potential of Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review. Hormone and Metabolic Research. 2026;58(03):81-89. doi:10.1055/a-2787-1205
BibTeX
@article{AlRashid2026,
author = {Al Rashid, Sulthan and Suriyan, Arun and Bilal Azam, Mohamed and Balasubramanian, Rajkapoor and Pakkir Maideen, Naina Mohamed and Chidambaram, Kumarappan and Amirthalingam, Palanisamy},
title = {Exploring the Therapeutic Potential of Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review},
journal = {Hormone and Metabolic Research},
year = {2026},
volume = {58},
number = {03},
pages = {81--89},
doi = {10.1055/a-2787-1205}
}
EUVIMED